Pharmaceutical treatment and implementation of cardiac rehabilitation programs have improved the prognosis of patients with acute myocardial infarction (AMI).
1 To achieve maximum benefit, compliance with medication intake and cardiac rehabilitation are essential for decreasing the risk of recurrent AMI, heart failure, and cardiovascular mortality. A recent study
2 showed that nonadherence to β-blockers, angiotensin-converting enzyme inhibitors, and statins was associated with an increase in cardiovascular-associated and all-cause mortality in patients with coronary artery disease. Other studies
3 have shown that patients who are better informed are more adherent to therapy. Therefore, there is a need for an intervention that may help to improve the compliance of patients with guideline-based therapy.